BrightInsight builds a patient persistence platform for life sciences companies that predicts and prevents therapy drop-off. The company unifies patient experiences, detects behavioral signals that precede discontinuation, and triggers tailored interventions to keep patients on therapy longer—improving health outcomes and reclaiming commercial value for brands.

Our regulated digital health platform supports product-scale patient-facing solutions and clinical-grade software across multiple therapeutic areas, including cardiovascular, diabetes, oncology, rare diseases, gene therapy, immunology, and neurology.

Trusted by leading life sciences companies and partners (for example Sanofi and CSL), BrightInsight focuses on measurable improvements in adherence, persistence, and long-term patient value.